Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
JMJD1C antisense RNA 1 (JMJD1C-AS1) is a long non-coding RNA transcribed from the DNA strand antisense to the protein-coding JMJD1C locus. This RNA does not encode a protein and is not classified as a receptor, enzyme, transporter, or other classical drug target. There is currently no published evidence establishing JMJD1C-AS1 as a therapeutic target or providing clear details about its molecular function, involvement in human disease, interaction with drugs, or role as a biomarker. Most available scientific and clinical research focuses on the JMJD1C protein rather than this antisense RNA. JMJD1C-AS1 is not the same as JMJD1C; the former is a lncRNA, while the latter is a protein-coding gene frequently implicated in leukemia and epigenetic regulation. There is currently no evidence that JMJD1C-AS1 has recognized therapeutic utility or clear biological/disease function (as of 2024). Mention of JMJD1C-AS1 is limited to genomic annotation resources, with no definitive literature linking it to clinical targets or disease pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on JMJD1C antisense RNA 1 (JMJD1C-AS1).